Back Pain News and Research

Latest Back Pain News and Research

Mother’s miracle surgery for cancer - body cut in half

Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.

23 Sep 2010

FDA approves Gilenya capsules for reducing MS relapses

The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

22 Sep 2010

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics Pharmaceuticals, Inc. today announced the completion of the treatment phase of a 1,034-patient, one-year, open-label, international, phase 3 safety study of methylnaltrexone bromide subcutaneous injection in chronic, non-malignant pain patients with opioid-induced constipation (OIC).

22 Sep 2010

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

20 Sep 2010

UCLA conference to provide information about latest developments to help enhance quality of life of seniors

While aging impacts everyday living in many ways, the latest technologies in the medical, consumer and lifestyle fields have the potential to help older adults live better for longer.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Endoscopic laser spine procedures replace traditional open back surgery

The Bonati Spine Institute, the leading center for the patented Bonati Spine Procedures for minimally invasive laser spine surgery, supports recent studies by highly respected organizations such as the Journal of the America Board of Family Medicine and Consumer Reports reporting an unnecessary growth in tests and treatments targeting back pain.

16 Sep 2010

Bohai adds additional pharmaceutical products to Traditional Chinese Medicine portfolio

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced the introduction of five additional pharmaceutical products to its portfolio of TCM offerings.

15 Sep 2010

FDA-cleared LaserTouchOne device for chronic and acute pain treatment available without prescription

The American Pain Foundation reports that despite the fact that the majority of the U.S. population looks healthy, statistics tell a different story: Approximately 1 in 3 Americans suffer from chronic pain. This chronic pain could be related to an illness like cancer or rheumatoid arthritis, or a condition such as arthritis, migraine headaches, fibromyalgia or back pain from a car accident.

15 Sep 2010

Fusion surgery for spondylolisthesis in lumbar spine has long-term benefits: Study

A group of children who underwent fusion surgery for spondylolisthesis in the lumbar spine 30 years ago showed a clear reduction in back pain when followed up seven years later. A new study of these patients as adults has found that the benefits have lasted, reveals research from the Sahlgrenska Academy and Sahlgrenska University Hospital presented this week at the International Society of Orthopaedic Surgery and Traumatology (SICOT) annual international conference in Gothenburg.

13 Sep 2010

Ranier's Cadisc-L spinal disc replacement granted CE Mark Approval

Ranier Technology, the medical device development company focusing on the commercialisation of spinal implants, has announced that it has received CE Mark approval for its Cadisc™-L; an elasto-mimetic spinal disc replacement device for the lumbar spine. The CE Mark approval was received following a review of the company's multi-centre European clinical study and its extensive portfolio of biocompatibility and biomechanical testing.

13 Sep 2010

FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

13 Sep 2010

Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010

Purdue Pharma L.P. will present data from the clinical program for Butrans™ (buprenorphine) Transdermal System CIII in a series of posters at PAINWeek®2010, September 8-10 in Las Vegas.

10 Sep 2010

C.A.R.E.S. Alliance launches online tools for addressing misuse and abuse of pain medications

The C.A.R.E.S. Alliance, a new patient safety organization, today launched a range of online tools designed to help solve the growing problem of misuse and abuse of opioids by identifying the risks associated with these powerful pain medications. The free resources offered through the C.A.R.E.S. (Collaborating & Acting Responsibly to Ensure Safety) Alliance promote safety in prescribing, dispensing, using, storing and disposing of these commonly abused pain medications.

9 Sep 2010

Study finds acupuncture can control side effects of cancer treatment

Recent studies have shown that acupuncture can help control a number of symptoms and side effects such as pain, fatigue, dry mouth, nausea, and vomiting associated with a variety of cancers and their treatments.

3 Sep 2010

Celgene receives Paragraph IV Certification Letter on submission of ANDA for REVLIMID

Celgene Corporation today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration. The application requests authorization to manufacture and market generic versions of REVLIMID (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States.

3 Sep 2010

Accentus Medical signs licence agreement for Agluna anti-infective technology with Zimmer

Accentus Medical, a leading UK medical technology company that supplies advanced coatings and surface treatments to the medical device industry, announced today that it has signed a Licence and Services Agreement with Zimmer Holdings, Inc., a global market leader in musculoskeletal care. This agreement will enable the use of Accentus Medical's Agluna® anti-infective technology on a potentially broad range of Zimmer products.

3 Sep 2010

Study finds common risk factors linked with painkiller addiction

A new Geisinger study begins to unlock the puzzle of painkiller (opioid) addiction - why some people are more likely to become addicted than others. Geisinger investigators have found that patients with four common risk factors have a significantly higher risk of addiction. In addition, a history of severe drug dependence and drug abuse compounds the risk.

30 Aug 2010

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.

27 Aug 2010

New vibration technology to reduce stubborn stomach fat

For millions of dieters it seems impossible to lose belly fat no matter however carefully they watch what they eat or how many sit-ups they do. Some people give up and blame it on genetics, metabolism or body type and simply accept it as a fact of life. For whatever the reason, many Americans discover that stubborn fat around the stomach and love handles will not melt away despite their best efforts. Now a fitness research company says there is an effective way to win the battle of the bulge without special diets, drinks or difficult exercises.

27 Aug 2010

Back Pain News and Research

Latest Back Pain News and Research

Mother’s miracle surgery for cancer - body cut in half

FDA approves Gilenya capsules for reducing MS relapses

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

UCLA conference to provide information about latest developments to help enhance quality of life of seniors

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Endoscopic laser spine procedures replace traditional open back surgery

Bohai adds additional pharmaceutical products to Traditional Chinese Medicine portfolio

FDA-cleared LaserTouchOne device for chronic and acute pain treatment available without prescription

Fusion surgery for spondylolisthesis in lumbar spine has long-term benefits: Study

Ranier's Cadisc-L spinal disc replacement granted CE Mark Approval

FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

Purdue Pharma to present Butrans Transdermal System CIII clinical program data at PAINWeek 2010

C.A.R.E.S. Alliance launches online tools for addressing misuse and abuse of pain medications

Study finds acupuncture can control side effects of cancer treatment

Celgene receives Paragraph IV Certification Letter on submission of ANDA for REVLIMID

Accentus Medical signs licence agreement for Agluna anti-infective technology with Zimmer

Study finds common risk factors linked with painkiller addiction

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

New vibration technology to reduce stubborn stomach fat

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Back Pain News and Research

Latest Back Pain News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in